Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Clinical trial approval / initiation
Hengrui Pharmaceuticals Launches Phase II Trial for SHR7280 to Treat Uterine Fibroids
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...
GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval
GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...
Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...
Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for Five Drug Candidates, Including IL-17A mAb for Psoriasis
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
WestGene Biopharma’s EB Virus-Targeting mRNA Vaccine WGc-043 Clears for Clinical Trials in China
WestGene Biopharma Co., Ltd., a biotechnology company based in Chengdu, has received approval from the...
Insilico Medicine’s ISM6331 Earns FDA Orphan Drug Designation for Mesothelioma Treatment
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
Haisco Pharmaceutical’s PDE4B Inhibitor HSK44459 Gets NMPA Green Light for Interstitial Lung Disease Clinical Trial
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...
Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...
Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...
Degen Biopharmaceutical’s DG01 PROTAC Drug Receives NMPA Clearance for Solid Tumor Studies
Suzhou Degen Biopharmaceutical Co., Ltd, a leading specialist in PROteolysis TArgeting Chimeras (PROTAC) technology in...
Yantai Dongcheng Pharmaceutical Secures NMPA Nod for PSMA-Targeted Radiotherapeutic Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...
Innovent Biologics and Sanegene Bio Commence Phase I Clinical Trial for Hypertension siRNA Drug
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, in collaboration with...
Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS
China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...
Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...